Alexander Ivanov, MD
Clinical Cardiac Electrophysiology · Bridgewater, NJNPI 1770583163
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.9%), travel and lodging and grants — rather than concentrated in one kind of arrangement. Medtronic accounts for 71.6% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2024 at $6,989 and has fallen 60.5% since, to $2,762 in 2025.
Across 244 payments — averaging $80.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$14K
- Biosense Webster, Inc.$2K
- Abbott$1K
- Amgen$310
- Biotronik Inc.$237
- Novartis$204
- plus $2K from 22 others
What the payments were for
- Grants$5,00026%
- Travel & lodging$6,69234%
- Food & beverage$7,60439%
- Education$2691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 94 | $14,007 |
| Biosense Webster, Inc. | 10 | $1,689 |
| Abbott | 19 | $1,319 |
| Amgen | 21 | $310 |
| Biotronik Inc. | 2 | $237 |
| Novartis | 12 | $204 |
| E.r. Squibb & Sons, L.L.C. | 14 | $201 |
| Pfizer | 11 | $164 |
| Edwards Lifesciences | 1 | $149 |
| Johnson & Johnson | 10 | $148 |
| Boehringer Ingelheim | 9 | $137 |
| Biotronik NRO, Inc. | 1 | $127 |
| Zimmer Biomet | 1 | $122 |
| Astellas Pharma US Inc | 1 | $100 |
| AstraZeneca | 7 | $97 |
| Boston Scientific | 3 | $96 |
| Esperion Therapeutics, Inc. | 5 | $74 |
| Philips North America LLC | 2 | $65 |
| Bardy Diagnostics, Inc. | 4 | $62 |
| Amarin Pharma, Inc. | 4 | $55 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $43 |
| Merck | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $28 |
| Acarix USA Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Cvrx, Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$1,324
- Micra$1,053
- Confirm Rx$762
- ATTAIN COMMAND + SUREVALVE$573
- BioMonitor$226
- OCTARAY MAPPING CATHETER$223
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$171
- Visia AF$150
- Edwards SAPIEN 3 Transcatheter Heart Valve$149
- JOT DX$143
- SelectSecure$131
- Prospera$127
- Neuro Plating System$122
- CareLink$122
How this compares
$19,565 in reported general payments places this provider in the 55th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.
See all clinical cardiac electrophysiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $131,255 |
| XareltoRivaroxaban | 59 | $65,687 |
| EntrestoSacubitril/Valsartan | 37 | $52,851 |
| JardianceEmpagliflozin | 33 | $29,890 |
| BrilintaTicagrelor | 33 | $16,030 |
| VascepaIcosapent Ethyl | 19 | $14,957 |
| Metoprolol Succinate | 112 | $3,188 |
| Carvedilol | 106 | $1,943 |
| Ranolazine ErRanolazine | 12 | $1,921 |
| Amlodipine Besylate | 149 | $1,814 |
| Atorvastatin Calcium | 102 | $1,153 |
| SotalolSotalol Hcl | 39 | $1,132 |
| Spironolactone | 76 | $791 |
| Amiodarone Hcl | 42 | $788 |
| Rosuvastatin Calcium | 69 | $767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $164 | $131,255120 claims |
| Johnson & JohnsonXarelto | $148 | $65,68759 claims |
| NovartisEntresto | $204 | $52,85137 claims |
| Boehringer IngelheimJardiance | $137 | $29,89033 claims |
| AstraZenecaBrilinta | $97 | $16,03033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.
Other clinical cardiac electrophysiology in Bridgewater
- Sanjukta SanyalBridgewater$44K
- Benjamin D SouzaCherry Hill$741K
- Suneet MittalParamus$722K
- George MarkHaddon Heights$312K
- Raffaele CorbisieroBrowns Mills$135K
- Emad AzizNewark$112K
- Marc RoelkeWest Orange$110K
- Arjun TheerthamParlin$102K
- Michael LinkGalloway$96K
- Grant SimonsEnglewood$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.